Lilly, however, noted that a pre-specified secondary analysis of pooled data showed statistically significant slowing of cognitive decline in patients with mild-to-moderate disease who were treated with its solanezumab compound.

FORBES: Lilly's Big Alzheimer's Bet: Will It Pay Off?